drugset / Trial / NCT03923361

Neural and Antidepressant Effects of Propofol (Phase 2)

NCT03923361

Phase 2/3 Withdrawn University of Utah
NaSingle-groupOpen-labelTreatment

Summary

Moderate-intensity propofol treatments will be administered to participants who are non-responders at the end of Phase 1.

Timeline

Start
2019-04-16
Primary completion
2024-03
Completion
2024-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Propofol Small molecule

Indications

No indication recorded.